Search results
The tables presented here display the risk estimates of CIN 3+, as well as CIN 2+ and cancer for every possible combinations of test result as the data permits. These risk scores are obtained at time points, 0 (immediate), 1, 2, 3, 4, and 5 years.
Updated US consensus guidelines for management of cervical screening abnormalities are needed to accommodate the 3 available cervical screening strategies: primary human papillomavirus (HPV) screening, cotesting with HPV testing and cervical cytology, and cer-vical cytology alone.
An interactive Excel model that evaluates the trade-offs of four cervical cancer screening approaches and five cervical precancer treatment scenarios, looking at number of women reached, effectiveness of approach, and associated costs.
Guidelines Overview. Links and resources related to cervical screening, management, and colposcopy guidelines and recommendations. Screening Guidelines. Screening recommendations for the identification of precursors and prevention of cervical cancer. View Screening Guidelines. Management Guidelines & the Enduring Guidelines Process.
24 wrz 2021 · Nature Communications - Computer-assisted diagnosis is key for scaling up cervical cancer screening, but current algorithms perform poorly on whole slide image analysis and generalization....
19 wrz 2024 · Updated United States consensus guidelines for management of cervical screening abnormalities are needed to accommodate the three available cervical screening strategies: primary human papillomavirus (HPV) screening, cotesting with HPV testing and cervical cytology, and cervical cytology alone.
The adoption of the USPSTF guidelines expands the recommended options for cervical cancer screening in average-risk individuals aged 30 years and older to include screening every 5 years with primary high-risk human papillomavirus (hrHPV) testing.
